Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report
Genetic fusion involving the ROS1 gene lead to the constitutive activation of its encoded tyrosine kinase, thereby acting as an oncogenic driver that promotes tumor cell proliferation. Numerous missense mutations in ROS1 are currently classified as variants of unknown significance, especially, mutat...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-05-01
|
| Rangatū: | Frontiers in Pharmacology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1777570/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|